In addition to serving as a national resource for HIV-related research, CNTN is affiliated with a number of specific research projects. Below are examples of projects that utilize CNTN resources. |
|
Brain Amyloid and HAND in the cART Era Cristian Achim, M.D., Ph.D. |
|
Agency: Award Number: |
The goal of this project is to validate the diagnostic value of amyloid monitoring in clinical specimens in individuals with increased genetic risk and identify potential therapeutic targets implicated in amyloid clearance. |
Cerebrospinal Fluid and Plasma Biomarkers of HIV-Related Neuropathology Alex Bryant/Ron Ellis, M.D., Ph.D. |
|
Agency: Award Number: |
The present study seeks to address the gap in the HAND biomarker literature by measuring an array of candidate biomarker molecules in CSF and plasma samples from HIV-infected patients and evaluating their relationship to measures of inflammation, gliosis, neuronal damage, and cerebrovascular disease in postmortem brain tissue and to antemortem measures of neurocognitive impairment. |
Genetics of Monooxygenase Activity & Methamphetamine-Related Brain Injury in HIV Mariana Cherner, Ph.D. |
|
Agency: Award Number: |
To examine the relationship between CYP2D6 and FMO3 genotypes and neuropathologic changes observed in brain tissue from METH dependent subjects who died with AIDS. |
Role of CYP2D6 in Cognitive and Motor Impairments Associated with Methamphetamine Dependence Mariana Cherner, Ph.D. |
|
Agency: Award Number: P30MH062512 (Developmental Award) |
To test the hypothesis that those meth users who develop NP impairments are more likely to be represented by phenotypes with deficient CYP2D6 alleles (PM and IM) than those who are NP normal, despite comparable exposure to meth. |
Role of Epigenetic Alterations in the Latency of HIV in the Human Brain Paula Desplats, Ph.D. |
|
Agency: Award Number: P30MH062512 (Developmental Award) |
This study will help determine the role of epigenetic alterations in the regulation of the latency of HIV in the human brain. |
ARC: Biomarkers/NC Impairment Igor Grant, M.D. |
|
Agency: Award Number: |
An administrative supplement to evaluate the relationship between biomarkers assessed in various fluids/compartments and the development of, or recovery from, HIV-associated neurocognitive disorders. |
Mechanisms of Neuroprotection in HIV Encephalitis Eliezer Masliah, M.D. |
|
Agency: Award Number: |
To investigate the role of alterations in CDK5 signaling pathway in the molecular mechanisms of synapto-dendritic damage triggered by HIV proteins, and to determine the involvement of the CDK5 signaling pathway in the mechanisms of defective neurogenesis triggered by HIV proteins. |
A Multi-System Study of HIV Neuropathogenesis: Genetics-Neuropathology-Behavior David Moore, Ph.D. |
|
Agency: Award Number: |
The goal of this study is to 1) identify associations between host genetic susceptibility loci and neuropathological intermediate phenotypes (NIPs) as measured via quantitative immunohistochemistry (IHC), and 2) determine the linear causative relationship between genetic susceptibility loci, NIPs, and neurocognitive impairment. |
Mannose Binding Lectin in Neuroinflammation and NeuroAIDS Kumud K. Singh, Ph.D. |
|
Agency: NIH/HNRC Award Number: P30MH062512 (Developmental Award) |
To analyze gene expression in PBMC samples derived from HIV-infected individuals with and without neurocognitive decline. |
Characterizing Proviral Populations in Brain Tissues David Smith, M.D. |
|
Agency: Award Number: |
This study is designed to develop and validate a combined next generation sequencing and bioinformatics platform to accurately measure and characterize HIV DNA populations in brain and lymph node tissues. |
Cerebral Vasomotor Effects on B-amyloid Deposition in the HIV-infected Brain Virawudh Soontornniyomkij, Ph.D. |
|
Agency: NIH/HNRC Award Number: P30MH062512 (Developmental Award) |
To study postmortem tissues from the frontal cortex, basal forebrain, and rostral pons of 40 HIV-infected patients and 10 HIV-seronegative controls, by immunohistochemistry to identify AB40 and AB42 deposits, neuronal tau pathology, and p75 neurotrophin receptor- and calbindin-immunoreactive neurons. |